Literature DB >> 33787088

Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.

Chee-Seng Yee1, Caroline Gordon2, David A Isenberg3, Bridget Griffiths4, Lee-Suan Teh5, Ian N Bruce6, Yasmeen Ahmad7, Anisur Rahman3, Athiveeraramapandian Prabu2, Mohammed Akil8, Neil McHugh9, Christopher J Edwards10, David D'Cruz11, Munther A Khamashta12, Vernon T Farewell13.   

Abstract

OBJECTIVE: To compare the responsiveness of the British Isles Lupus Assessment Group 2004 index (BILAG-2004) and the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) disease activity indices and to determine whether there was any added value in combining BILAG-2004, BILAG-2004 system tally (BST), or simplified BST (sBST) with SLEDAI-2K.
METHODS: This was a multicenter longitudinal study of SLE patients. Data were collected on BILAG-2004, SLEDAI-2K, and therapy on consecutive assessments in routine practice. The external responsiveness of the indices was assessed by determining the relationship between change in disease activity and change in therapy between 2 consecutive visits. Comparison of indices and their derivatives was performed by assessing the main effects of the indices using logistic regression. Receiver operating characteristic curves analysis was used to describe the performance of these indices individually and in various combinations, and comparisons of area under the curve were performed.
RESULTS: There were 1,414 observations from 347 patients. Both BILAG-2004 and SLEDAI-2K maintained an independent relationship with change in therapy when compared. There was some improvement in responsiveness when continuous SLEDAI-2K variables (change in score and score of previous visit) were combined with BILAG-2004 system scores. Dichotomization of BILAG-2004 or SLEDAI-2K resulted in poorer performance. BST and sBST had similar responsiveness as the combination of SLEDAI-2K variables and BILAG-2004 system scores. There was little benefit in combining SLEDAI-2K with BST or sBST.
CONCLUSION: The BILAG-2004 index had comparable responsiveness to SLEDAI-2K. There was some benefit in combining both indices. Dichotomization of BILAG-2004 and SLEDAI-2K leads to suboptimal performance. BST and sBST performed well on their own; sBST is recommended for its simplicity and clinical meaningfulness.
© 2021 American College of Rheumatology.

Entities:  

Mesh:

Year:  2022        PMID: 33787088      PMCID: PMC7613658          DOI: 10.1002/acr.24606

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  27 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

Review 3.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

4.  Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.

Authors:  Sean J Wollaston; Vernon T Farewell; David A Isenberg; Caroline Gordon; Joan T Merrill; Michelle A Petri; Kenneth C Kalunian
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.

Authors:  Chee-Seng Yee; Vernon T Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2011-01-18       Impact factor: 7.580

7.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

8.  The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally.

Authors:  Chee-Seng Yee; Caroline Gordon; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Vernon T Farewell
Journal:  Rheumatology (Oxford)       Date:  2012-08-20       Impact factor: 7.580

9.  The BILAG-2004 index is sensitive to change for assessment of SLE disease activity.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

10.  Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Authors:  Robert Zimmer; Hugo R Scherbarth; Oscar Luis Rillo; Juan Jesus Gomez-Reino; Sylviane Muller
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.